Navigation Links
High CTC levels predicted poor outcome in metastatic breast cancer
Date:12/10/2010

SAN ANTONIO A high level of circulating tumor cells (CTCs) cells that have detached from a tumor and are circulating in the body through the blood are an independent prognostic marker in metastatic breast cancer as first-line therapy. In addition, persistence of high CTC level during therapy was found to be an early marker of poor outcome.

"This is the largest, prospective series validating the prognostic value of CTCs in first-line chemotherapy metastatic breast cancer, independently from serum tumor markers for overall survival," said Jean-Yves Pierga, M.D., Ph.D., professor of the medical oncology department, Institut Curie and Universit Paris Descartes, France. "Persistence of a high level of CTCs before the second cycle of chemotherapy was a strong and early predictive marker of poor outcome."

Pierga presented results of this study at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held here Dec. 8-12, 2010.

Breast cancer can metastasize from a primary tumor in the breast to distant organs, such as the liver, lungs or bone, through the blood. New techniques have allowed for the detection of metastasis by testing blood for CTCs.

Previous research has not established that routine use of CTC measurements can improve patient outcomes, therefore, it is not currently a recommended practice, said Pierga.

The researchers prospectively tested CTCs as an outcome predictor compared with serum tumor markers in metastatic breast cancer patients treated by first-line chemotherapy. Serum tumor markers are proteins or glycoproteins released into the blood; however, tumor markers only indirectly reflect the presence of cancer and can be associated with dead cells, according to Pierga. In fact, some breast cancers can metastasize without any increase in tumor serum markers.

This study included 267 patients with metastatic breast cancer who were receiving first-line chemotherapy and had undergone assessment for three tumor markers: CA 15.3, CEA and LDH. Patients were enrolled in one of five cancer centers in France between June 2007 and Sept. 2009, and were followed for a median of 16 months.

Sixty-five percent of the patients had one or more CTCs; 44 percent had five or more CTCs. Of the measured tumor markers, 64 percent of patients had high CA 15.3, 51 percent had high CEA and 45 percent had high LDH.

High CTC levels were predictive of poor progression-free survival and overall survival, independent of serum tumor markers.

Evaluation of serum tumor markers showed that baseline levels of CA 15.3, CEA and LDH were prognostic for poor progression-free survival, but only LDH was prognostic for overall survival. CTCs were highly associated with tumor markers, tumor burden, performance status, and number of metastatic sites, but were also independent of tumor biology, such as HER2 status, or grade of cancer.

"CTCs add an independent prognostic marker in metastatic breast cancer at first-line chemotherapy, and an early predictive marker of clinical benefit after one cycle of chemotherapy," Pierga said.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Both High, Low Levels of Vitamin D in Older Women May Be Problematic
2. Lower levels of education are associated with increased risks of heart failure
3. Low and high vitamin D levels in older women associated with increased likelihood of frailty
4. Youth Sports Injuries Reaching Epidemic Levels, Experts Report
5. AgriLife researchers find way to cut food-irradiation levels by half
6. Genes Influence Vitamin D Levels, But Only in Winter: Study
7. Study Sees Link Between Low Salt Levels, Fracture Risk in Older Adults
8. Experimental Drug Raises Good Cholesterol Levels in Early Trial
9. Yogas ability to improve mood and lessen anxiety is linked to increased levels of a critical brain chemical
10. High Carcinogen Levels Seen in Kids Living With Smokers
11. Insufficient vitamin D levels in CLL patients linked to cancer progression and death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology: